These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 30678050)

  • 1. Inhibition of Heme Oxygenase-1 Activity Enhances Wilms Tumor-1-Specific T-Cell Responses in Cancer Immunotherapy.
    Schillingmann DA; Riese SB; Vijayan V; Tischer-Zimmermann S; Schmetzer H; Maecker-Kolhoff B; Blasczyk R; Immenschuh S; Eiz-Vesper B
    Int J Mol Sci; 2019 Jan; 20(3):. PubMed ID: 30678050
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A High-avidity WT1-reactive T-Cell Receptor Mediates Recognition of Peptide and Processed Antigen but not Naturally Occurring WT1-positive Tumor Cells.
    Jaigirdar A; Rosenberg SA; Parkhurst M
    J Immunother; 2016 Apr; 39(3):105-16. PubMed ID: 26938944
    [TBL] [Abstract][Full Text] [Related]  

  • 3. WT1 peptide-specific T cells generated from peripheral blood of healthy donors: possible implications for adoptive immunotherapy after allogeneic stem cell transplantation.
    Weber G; Karbach J; Kuçi S; Kreyenberg H; Willasch A; Koscielniak E; Tonn T; Klingebiel T; Wels WS; Jäger E; Bader P
    Leukemia; 2009 Sep; 23(9):1634-42. PubMed ID: 19357702
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro methods for generating CD8+ T-cell clones for immunotherapy from the naïve repertoire.
    Ho WY; Nguyen HN; Wolfl M; Kuball J; Greenberg PD
    J Immunol Methods; 2006 Mar; 310(1-2):40-52. PubMed ID: 16469329
    [TBL] [Abstract][Full Text] [Related]  

  • 5. WT1 is a tumor-associated antigen in colon cancer that can be recognized by in vitro stimulated cytotoxic T cells.
    Koesters R; Linnebacher M; Coy JF; Germann A; Schwitalle Y; Findeisen P; von Knebel Doeberitz M
    Int J Cancer; 2004 Apr; 109(3):385-92. PubMed ID: 14961577
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Immunotherapy for leukemia cells by using cytotoxic T lymphocyte specifically against WT1-derived peptide: an experimental study in vitro].
    Gu WY; Cao XS; Qiu GQ; Chen ZX; Sheng LX; Xie XB; He J; Cen JN; Shen HL
    Zhonghua Yi Xue Za Zhi; 2005 Dec; 85(49):3475-80. PubMed ID: 16686063
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cancer immunotherapy targeting WT1 protein.
    Sugiyama H
    Int J Hematol; 2002 Aug; 76(2):127-32. PubMed ID: 12215010
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Graft-versus-leukemia effect with a WT1-specific T-cell response induced by azacitidine and donor lymphocyte infusions after allogeneic hematopoietic stem cell transplantation.
    Ishikawa T; Fujii N; Imada M; Aoe M; Meguri Y; Inomata T; Nakashima H; Fujii K; Yoshida S; Nishimori H; Matsuoka KI; Kondo E; Maeda Y; Tanimoto M
    Cytotherapy; 2017 Apr; 19(4):514-520. PubMed ID: 28139337
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modulation of heme oxygenase-1 by metalloporphyrins increases anti-viral T cell responses.
    Bunse CE; Fortmeier V; Tischer S; Zilian E; Figueiredo C; Witte T; Blasczyk R; Immenschuh S; Eiz-Vesper B
    Clin Exp Immunol; 2015 Feb; 179(2):265-76. PubMed ID: 25196646
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of a highly immunogenic HLA-A*01-binding T cell epitope of WT1.
    Asemissen AM; Keilholz U; Tenzer S; Müller M; Walter S; Stevanovic S; Schild H; Letsch A; Thiel E; Rammensee HG; Scheibenbogen C
    Clin Cancer Res; 2006 Dec; 12(24):7476-82. PubMed ID: 17189421
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical Grade Production of Wilms' Tumor-1 Loaded Cord Blood-Derived Dendritic Cells to Prevent Relapse in Pediatric AML After Cord Blood Transplantation.
    Plantinga M; Lo Presti V; de Haar CG; Dünnebach E; Madrigal A; Lindemans CA; Boelens JJ; Nierkens S
    Front Immunol; 2020; 11():559152. PubMed ID: 33101274
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Simultaneous in vitro generation of CD8 and CD4 T cells specific to three universal tumor associated antigens of WT1, survivin and TERT and adoptive T cell transfer for the treatment of acute myeloid leukemia.
    Sohn HJ; Lee JY; Lee HJ; Sohn DH; Cho HI; Kim HJ; Kim TG
    Oncotarget; 2017 Jul; 8(27):44059-44072. PubMed ID: 28477011
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification and characterization of a WT1 (Wilms Tumor Gene) protein-derived HLA-DRB1*0405-restricted 16-mer helper peptide that promotes the induction and activation of WT1-specific cytotoxic T lymphocytes.
    Fujiki F; Oka Y; Tsuboi A; Kawakami M; Kawakatsu M; Nakajima H; Elisseeva OA; Harada Y; Ito K; Li Z; Tatsumi N; Sakaguchi N; Fujioka T; Masuda T; Yasukawa M; Udaka K; Kawase I; Oji Y; Sugiyama H
    J Immunother; 2007 Apr; 30(3):282-93. PubMed ID: 17414319
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression.
    Oka Y; Tsuboi A; Taguchi T; Osaki T; Kyo T; Nakajima H; Elisseeva OA; Oji Y; Kawakami M; Ikegame K; Hosen N; Yoshihara S; Wu F; Fujiki F; Murakami M; Masuda T; Nishida S; Shirakata T; Nakatsuka S; Sasaki A; Udaka K; Dohy H; Aozasa K; Noguchi S; Kawase I; Sugiyama H
    Proc Natl Acad Sci U S A; 2004 Sep; 101(38):13885-90. PubMed ID: 15365188
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HLA-DPB1*05: 01-restricted WT1332-specific TCR-transduced CD4+ T lymphocytes display a helper activity for WT1-specific CTL induction and a cytotoxicity against leukemia cells.
    Lin Y; Fujiki F; Katsuhara A; Oka Y; Tsuboi A; Aoyama N; Tanii S; Nakajima H; Tatsumi N; Morimoto S; Tamanaka T; Tachino S; Hosen N; Nishida S; Oji Y; Kumanogoh A; Sugiyama H
    J Immunother; 2013 Apr; 36(3):159-70. PubMed ID: 23502763
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Direct recognition and lysis of leukemia cells by WT1-specific CD4+ T lymphocytes in an HLA class II-restricted manner.
    Guo Y; Niiya H; Azuma T; Uchida N; Yakushijin Y; Sakai I; Hato T; Takahashi M; Senju S; Nishimura Y; Yasukawa M
    Blood; 2005 Aug; 106(4):1415-8. PubMed ID: 15845894
    [TBL] [Abstract][Full Text] [Related]  

  • 17. WT1-specific T cell receptor gene therapy: improving TCR function in transduced T cells.
    Stauss HJ; Thomas S; Cesco-Gaspere M; Hart DP; Xue SA; Holler A; King J; Wright G; Perro M; Pospori C; Morris E
    Blood Cells Mol Dis; 2008; 40(1):113-6. PubMed ID: 17855129
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro stimulation with WT1 peptide-loaded Epstein-Barr virus-positive B cells elicits high frequencies of WT1 peptide-specific T cells with in vitro and in vivo tumoricidal activity.
    Doubrovina ES; Doubrovin MM; Lee S; Shieh JH; Heller G; Pamer E; O'Reilly RJ
    Clin Cancer Res; 2004 Nov; 10(21):7207-19. PubMed ID: 15534094
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Non-transplantable cord blood units as a source for adoptive immunotherapy of leukaemia and a paradigm of circular economy in medicine.
    Koukoulias K; Papadopoulou A; Kouimtzidis A; Papayanni PG; Papaloizou A; Sotiropoulos D; Yiangou M; Costeas P; Anagnostopoulos A; Yannaki E; Kaloyannidis P
    Br J Haematol; 2021 Jul; 194(1):158-167. PubMed ID: 34036576
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Wilms' tumor 1-specific cytotoxic T lymphocytes can be expanded from adult donors and cord blood.
    Krishnadas DK; Stamer MM; Dunham K; Bao L; Lucas KG
    Leuk Res; 2011 Nov; 35(11):1520-6. PubMed ID: 21774984
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.